Indication name: Neonatal Seizure
Neonatal Seizure – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China)
The most common identifiable
causes are hypoxic-ischaemic encephalopathy-HIE, cerebral infarction, cerebral
trauma, central nervous system infection, metabolic abnormalities including
hypoglycaemia, narcotic drug withdrawal, etc.
Clinical classification of
neonatal seizures: Subtle, Clonic, Myoclonic and Tonic
Newborn babies have a central
nervous system that is vulnerable to epileptogenic activity, and as a result
they have a relatively high incidence of seizures (12 per 1,000 term infants).
Competitive landscape of Neonatal
Seizure includes country specific approved as well as pipeline therapies. Any
asset/ product specific designation or review and Accelerated Approval are
being tracked and supplemented with analyst commentary.
KOLs
insights of Neonatal Seizure across 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Neonatal Seizure Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Stage
1 Lacosamide UCB Biopharma SRL Phase 3
2 Phenobarbital Sodium Injection NEMA Research, Inc. Phase 3"
No comments:
Post a Comment